Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL752037 | 1.00 | RIPK1 (0.52) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL1824156 | 0.88 | RIPK1 (0.48) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL9764565 | 0.85 | RIPK1 (0.46) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL29026695 | 0.83 | TYR (0.48) | RIPK1 | |
| SCHEMBL11340864 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28045674 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28039437 | 0.82 | STAT3 (0.46) | RIPK1 | |
| SCHEMBL28336920 | 0.81 | HDAC4 (0.41) | RIPK1 | |
| SCHEMBL4578844 | 0.81 | RIPK1 (0.53) | RIPK1TAAR1TRPA1AOC3 | |
| SCHEMBL7235718 | 0.80 | HRH1 (0.50) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | RIPK1 1542/4885TAAR1 2410/4885TRPA1 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.